Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data
GLP-1RAs were associated with reduced pancreatic cancer incidence in patients with type 2 diabetes mellitus. Further studies and trials are needed to explore mechanisms and confirm causal effects.
Authors
- Lindsey Wang
- Rong Xu (ORCID: https://orcid.org/0000-0003-3127-4795)
- QuanQiu Wang
- David C. Kaelber (ORCID: https://orcid.org/0000-0001-7855-9515)
- Li Li (ORCID: https://orcid.org/0000-0003-1802-9517)
Institutions
- MetroHealth (US)
- University of Virginia Cancer Center
- University of Virginia (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1093/jnci/djae260
- Citations
- 35
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 9.89
Funders
- American Cancer Society
- Case Comprehensive Cancer Center, Case Western Reserve University
- National Cancer Institute
- National Center for Advancing Translational Sciences